Introduction
CiMaas develops immunotherapy for cancer by optimally engaging the immune system.
Read more about CiMaas Immunotherapy products,
or watch our video.
This week CiMaas reached an agreement with several parties for a restart.
We are happy to announce that we are able to continue activities on our cell products. Further details will be communicated soon.
To our greatest regret CiMaas has filed for bankruptcy, which became effective Tuesday June 11, 2024. Although CiMaas has great assets in the field of NK cell immunotherapy for cancer using its proprietary feeder cell technology and expansion methodology, it was unable to raise enough financial resources to perform the required clinical studies.
Under the agreement, CiMaas will provide CYTEA BIO with the GMP-grade K562-F012 feeder cells for the expansion of its umbilical cord blood-derived NK cells. Conversely, CYTEA BIO will supply CiMaas with Pin™ antibodies for the pre-arming of CiMaas NK cells to assess the benefit it brings and the opportunity to pursue a longer-term partnership.